Hoth: Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer

 Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused biopharmaceutical company, announced today that it has received approval from the University of Miami to enroll patients for its first in human clinical trial of HT-001.

This First-in-Human (FIH) Phase 2a clinical trial of HT-001 for the treatment of skin toxicities associated with Epidermal Growth Factor Receptor Inhibitors (EGFRi). This clinical trial is a randomized, placebo-controlled, parallel Phase 2a dose-ranging study to investigate the efficacy, safety, and tolerability of topical HT-001 for the treatment of skin toxicities associated with EGFRi. More information can be found at clinicaltrials.gov.

https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-expansion-of-fda-cleared-first-in-human-clinical-trial-for-cancer-patients-of-ht-001-at-university-of-miami-302022630.html